Keywords
How to Cite
Abstract
Hormonal imbalance of the thyroid gland is a pathological state that disrupts fundamental metabolic processes within the organism, necessitating prolonged and rigorous pharmacotherapy. The synthetic drugs employed in the management of hypothyroidism and thyrotoxicosis (levothyroxine sodium, thiamazole, propylthiouracil) possess a notoriously narrow therapeutic window; failure to individualize their pharmacokinetic and pharmacodynamic profiles precipitates severe iatrogenic complications. This study aims to comprehensively analyze the clinico-pharmacological parameters of drugs affecting thyroid function, the risks of drug-drug interactions, and contemporary models of therapeutic drug monitoring. Within a prospective clinico-laboratory design, the pharmacotherapeutic efficacy of 210 patients with thyroid pathology (120 with hypothyroidism, 90 with diffuse toxic goiter) was evaluated over an 18-month observational period. Dispersion and multivariate regression analyses revealed that among patients co-administering levothyroxine sodium with proton pump inhibitors (omeprazole) or calcium supplements, 38.4% exhibited persistent subclinical hypothyroidism (TSH > 4.5 mIU/L) attributable to a precipitous decline in drug bioavailability (a 32% reduction in absorption). In the antithyroid therapy cohort, it was confirmed that a high initial dose of thiamazole (> 30 mg/day) independently multiplied the risk of hepatotoxicity (a 3-fold elevation in ALT and AST) by a factor of 4.2 (p < 0.001) without accelerating clinical efficacy. The integral evaluation of hormonal regulation via thyroid-stimulating hormone (TSH) and free thyroxine (fT4) monitoring within a unified clinico-pharmacological panel (AUC = 0.894) equips clinical practitioners with a highly accurate objective substrate for calibrating drug dosages to body mass, age, and comorbid conditions, thereby minimizing the risks of cardiovascular complications and osteoporosis during long-term therapy.
References
1. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 15th ed. New York: McGraw Hill; 2021.
2. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-1751.
3. Biondi B, Wartofsky L. Treatment with thyroid hormone. Endocrine Reviews. 2019;35(3):433-512.
4. Kahaly GJ, Bartalena L, Hegedüs L, et al. 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism. European Thyroid Journal. 2018;7(4):167-186.
5. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
6. Virili C, Antonelli A, Santaguida MG, et al. Gastrointestinal Malabsorption of Thyroxine. Endocrine Reviews. 2019;40(1):118-136.
7. Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Practice & Research Clinical Endocrinology & Metabolism. 2019;23(6):781-792.
8. Burch HB, Cooper DS. Management of Graves' Disease: A Review. JAMA. 2015;314(23):2544-2554.
9. Maciel RM, Spencer CA. Methodological aspects of thyroid function testing. Endocrinology and Metabolism Clinics of North America. 2020;49(3):361-378.
10. Zulfiqar AA, Andres E. Drug safety, pharmacokinetics, and the role of rigorous clinical trials in modern medicine. Journal of Clinical Pharmacology. 2021;61(3):289-301.
11. Cooper DS. Antithyroid drugs. New England Journal of Medicine. 2005;352(9):905-917.
12. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nature Reviews Endocrinology. 2018;14(5):301-316.